Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Non-Current Deffered Revenue (2016 - 2025)

Tandem Diabetes Care's Non-Current Deffered Revenue history spans 11 years, with the latest figure at $8.5 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 18.95% year-over-year to $8.5 million; the TTM value through Dec 2025 reached $8.5 million, down 18.95%, while the annual FY2025 figure was $8.5 million, 18.95% down from the prior year.
  • Non-Current Deffered Revenue reached $8.5 million in Q4 2025 per TNDM's latest filing, down from $8.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $19.1 million in Q3 2022 to a low of $8.5 million in Q4 2025.
  • Average Non-Current Deffered Revenue over 5 years is $13.5 million, with a median of $13.3 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: decreased 0.39% in 2022, then decreased 26.4% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $16.9 million in 2021, then decreased by 0.39% to $16.9 million in 2022, then fell by 21.0% to $13.3 million in 2023, then dropped by 21.57% to $10.5 million in 2024, then dropped by 18.95% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Non-Current Deffered Revenue are $8.5 million (Q4 2025), $8.8 million (Q3 2025), and $9.6 million (Q2 2025).